abstract |
The present invention reduces the plasma levels of novel β-substituted β-aminoethyl phosphonate derivatives and apo (a), Lp (a), apo B, apo B related lipoproteins (low density lipoprotein and ultra low density lipoprotein) And their use to reduce plasma levels of cholesterol. |